(19)
(11)EP 3 065 779 B1

(12)EUROPEAN PATENT SPECIFICATION

(45)Mention of the grant of the patent:
26.06.2019 Bulletin 2019/26

(21)Application number: 14802477.1

(22)Date of filing:  03.11.2014
(51)International Patent Classification (IPC): 
A61K 47/36(2006.01)
A61K 38/08(2019.01)
(86)International application number:
PCT/GB2014/053254
(87)International publication number:
WO 2015/063510 (07.05.2015 Gazette  2015/18)

(54)

DELIVERY OF DRUGS

FREISETZUNG VON WIRKSTOFFEN

ADMINISTRATION DE MÉDICAMENTS


(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 04.11.2013 GB 201319437

(43)Date of publication of application:
14.09.2016 Bulletin 2016/37

(73)Proprietor: Nanomerics Ltd.
St Albans, Hertfordshire AL1 1SR (GB)

(72)Inventors:
  • UCHEGBU, Ijeoma
    St Albans Hertfordshire AL1 1SR (GB)
  • SCHATZLEIN, Andreas
    St Albans Hertfordshire AL1 1SR (GB)
  • GODFREY, Lisa
    Chelmsford Essex CM3 1GZ (GB)
  • LALATSA, Katerina
    Portsmouth Hampshire PO5 2HA (GB)
  • IANNITELLI, Antonio
    London Greater London E3 3BF (GB)

(74)Representative: Creek, Isobel Clare 
The IP Asset Partnership Limited Prama House 267 Banbury Road
Oxford OX2 7HT
Oxford OX2 7HT (GB)


(56)References cited: : 
US-A1- 2010 222 281
  
  • UCHEGBU I F ET AL: "POLYMERIC CHITOSAN-BASED VESICLES FOR DRUG DELIVERY", JOURNAL OF PHARMACY AND PHARMACOLOGY, JOHN WILEY & SONS LTD, LONDON; GB, vol. 50, no. 5, 1 May 1998 (1998-05-01), pages 453-458, XP000863265, ISSN: 0022-3573
  • KUMAR MANOJ ET AL: "Evaluation of neuropeptide loaded trimethyl chitosan nanoparticles for nose to brain delivery", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol. 61, 2 July 2013 (2013-07-02), pages 189-195, XP028729244, ISSN: 0141-8130, DOI: 10.1016/J.IJBIOMAC.2013.06.041 cited in the application
  
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


Description

Field of the Invention



[0001] The present invention relates to a new system for the intranasal delivery of drugs to the brain.

Background to the Invention



[0002] The treatment of diseases of the brain is significantly limited by the blood brain barrier. Over the last decade intranasal administration of drugs has gained increasing interest as a non-parenteral therapy. Originally seen as a route of administration for the local treatment of congestion, infection, rhinitis or nasal polyposis, in recent years a variety of products have entered the market for the systemic treatment of a variety of ailments. Nasal delivery of drugs has many advantages, including avoidance of first pass metabolism and degradation in the gut, rapid onset with quick diffusion into the systemic system that parallels with intravenous administration and patient compliance due to the non-invasive nature and ease of self-medication.

[0003] Within the nasal passage there are two main areas of absorption: the respiratory zone, which has the largest surface area and is highly vascularised, where active principles can cross the epithelium via para-or-transcellular routes, and the olfactory epithelium. The latter comprises only 3-5% of the total surface area of the nasal cavity and therefore is not largely involved in systemic absorption, but can allow direct access to the CNS, bypassing the blood brain barrier via the processes of olfactory neurons, through to the synaptic junctions with neurons of the olfactory bulb.

[0004] There are physical disadvantages associated with administration via the nasal route that must be overcome. These include mucociliary clearance, enzymatic activity of the nasal mucosa, peptidases and drug metabolising enzymes. In addition, molecular weight and lipophilicity play a part in absorption - low molecular weight molecules having a molecular weight less than 300Da tend to be rapidly absorbed whereas for molecules between 300-1000Da, liposolubility is an important property. Lipophilic molecules diffuse freely, whereas it is thought that hydrophilic molecules must pass through the paracellular route. Molecules with a molecular weight above 1kDa absorb very slowly and have a low bioavailability. These barriers can be addressed by altering the physiochemical properties of the molecule, increasing permeability by coadministration of an absorption promoter or reducing excretion/degradation by co-administering inhibitors. Absorption promoters currently under development include alkylsaccharides (Intravail®), chitosan (ChiSys™), low methylated pectin (PecSys™) and polyethylene glycol (30%).

[0005] Chitosan and its derivatives are commonly used as absorption enhancers due to chisosan's well documented ability to facilitate paracellular transport by opening the tight junctions or by interacting with extra-cellular matrix components. Chitosan increases the bioavailability of verapamil when administered nasally to rabbits in comparison to nasal verapamil solution (Abdel Mouez et al; Eur J Pharm Sci 2013, 30, 59-66). In addition, polylactic acid nanoparticles modified with chitosan have been used to encapsulate the analgesic peptide Neurotoxin. Rats intranasally administered with these chitosan modified nanoparticles had an increased concentration of neurotoxin in the periaqueductal gray in comparison to polylactic acid alone loaded nanoparticles (Zhang et al; Drug Development and Industrial Pharmacy 2013, 39, (11), 1618-24).

[0006] Endogenous opioid peptides Leucine5-enkephalin (LENK) and Methionine5-enkephalin (MENK) are mainly degraded by cleavage of the N-terminal tyrosine. In the presence of polycarbophil-cysteine (0.25%) and glutathione (1%) LENK has shown reduced degradation and enhanced transportation across freshly excised bovine nasal mucosa. The absorption enhancer sodium glycocholate and protease inhibiter puromycin co-administered with LENK reduced degradation in nasal washings. However this combination of excipients can lead to cell leakage and therefore toxicity.

[0007] Chitosan formulations can also reduce the degradation of peptides. For instance, a chitosan-EDTA conjugate has been shown to reduce the degradation of LENK (Bernkop-Schnurch et al; 1997, Pharm Res 14, 917-22). LENK has also been nasally administered with trimethyl chitosan nanoparticles and shown enhanced antinociception in two mouse pain models in comparison to LENK alone (Kumar et al; Int J Biol Macromol 2013, 61C, 189-195).

[0008] WO2004/026912 describes polysaccharides which are used to solubilise hydrophobic drugs. The polysaccharides are amphiphilic and are generally selected from any derivatives of the following: chitosans, dextrans, alginic acids, starches, dextran and guar gums. Quaternary ammonium palmitoyl glycol chitosan (GCPQ) and quaternary ammonium hexadecyl glycol chitosan (GCHQ) are used in the Examples of this patent application as solubilising polysaccharides.

[0009] WO2008/017839 describes micellar clusters formed from amphiphilic carbohydrate polymers and their use in formulating hydrophobic drugs. GCPQ is specifically exemplified as an amphiphilic carbohydrate polymer.

[0010] In US8278277 a lipid ester prodrug of LENK is formed and added to a composition comprising GCPQ. The compositions are delivered intravenously or orally. The prodrug was converted to LENK in vivo and shown to result in significant LENK brain levels. However, none of these prior art patent publications discuss formulations involving hydrophilic drugs per se.

Summary of the Invention



[0011] In accordance with a first aspect of the invention there is provided a composition comprising a hydrophilic neuroactive peptide drug and an amphiphilic carbohydrate compound represented by the general formula in claim 1, for use in the treatment of pain wherein the composition is intranasally administered to the human or animal body.

[0012] The amphiphilic carbohydrate compound is capable of self-assembly into nanoparticles in aqueous media.

[0013] Although chitosan and its derivatives are well documented for the delivery of drugs via the nasal route, nasal delivery with self-assembling amphiphilic carbohydrates such as GCPQ has not been reported. Unlike chitosan, which is soluble at acidic pH, GCPQ is capable of self-assembly at neutral pH, and this confers an advantage over its parent compound for nasal delivery. We believe that the addition of the palmitoyl chain to chitosan enables this chitosan derivative to self-assemble and confers greater association with drug compounds and therefore enhanced delivery.

[0014] Furthermore, GCPQ is not thought to function in the same manner as the documented chitosan derivatives. Chitosan (Artusson, P., et al; 1994. 11 1358-1361) and trimethyl chitosan (Thanou, M.M., et al; Journal of Controlled Release, 2000, 64, 15-25) open intercellular tight junctions and are believed to promote membrane permeabilisation and hydrophilic drug absorption through this mechanism even when administered intranasally (Kumar, M., et al; International Journal of Biological Macromolecules, 2013, 61, 189-95). Amphiphilic self-assembling chitosans such as GCPQ amphiphiles do not open intercellular junctions (Siew, A., et al; Molecular Pharmaceutics, 2012, 9, 14-28). Hence the ability of amphiphilic carbohydrate compounds such as GCPQ to facilitate the delivery of hydrophilic drugs was unexpected.

Detailed Description of the Invention



[0015] By hydrophilic, is meant a compound with high water solubility (> 1mg mL-1).

[0016] The invention has particular utility for the delivery of hydrophilic drugs to the brain. We have shown that the drug, delivered in accordance with the invention, is able to have a therapeutic effect in the brain.

[0017] The hydrophilic drug is a neuroactive peptide. Peptides are of tremendous clinical value for the treatment of many central nervous system (CNS) disorders, and preferably therefore the drug is a CNS active drug. Many existing peptide pharmaceuticals are rendered ineffective after oral administration or are unable to cross the blood brain barrier (BBB) mainly due to their hydrophilicity, size, charge and rapid metabolic degradation in the gastrointestinal tract, nasal cavity and blood, as detailed above. Since the invention has particular utility for delivering drugs to the brain, the hydrophilic drug is preferably a neuroactive agent.

[0018] Endogenous opioid neuropeptides, preferably neuropentapeptides are particularly preferred drugs for use in this invention. Examples include MENK and LENK.

[0019] The drug is used to treat pain.

[0020] Preferred drugs include neuropeptides: enkephalin, neuropeptide S, dalargin, orexin, vasopressin, leptin, cholecystokinin, dynorphin, detorphin I, neurotensin and oxytocin.

[0021] The amphiphilic carbohydrate compound is represented by the formula:

wherein a + b + c+ d = 1.000 and

a is between 0.00 and 0.970

b is between 0.01 and 0.990,

c is between 0.000 and 0.970, and

d is between 0.01 and 0.990;

and wherein:

X is a hydrophobic group;

R1, R2 and R3 are independently selected from a substituted or unsubstituted alkyl group;

R4, R5, R6 and R10 are independently selected from hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted ether group, or a substituted or unsubstituted alkene group;

R7 may be present or absent and, when present, is an unsubstituted or substituted alkyl group, an unsubstituted or substituted amine group or a substituted or unsubstituted amide group;

R8 and R9 are independently selected from hydrogen and either a substituted or unsubstituted alkyl group, a substituted or unsubstituted ether group, or a substituted or unsubstituted alkene group;

or a salt thereof.



[0022] In the above general formula, the a, b, c and d units may be arranged in any order and may be ordered, partially ordered or random. The * in the formula is used to indicate the continuing polymer chain. In preferred embodiments, the molar proportion of the d units is greater than 0.01, and more preferably is at least 0.110, more preferably is at least 0.120, more preferably is at least 0.150 or in some embodiments is at least 0.18. Generally, the molar proportion of the d unit is 0.500 or less, and more preferably is 0.350 or less.

[0023] Preferably, the molar proportion of the b unit is between 0.010 and 0.800, and more preferably between 0.050 and 0.600.

[0024] Preferably, the molar proportion of the c unit is between 0.0200 and 0.850, and more preferably between 0.05 and 0.550.

[0025] Preferably the molar proportion of the a unit is between 0.05 and 0.85 and more preferably between 0.10 and 0.75.

[0026] As can be seen from the above formula, the a and c units may optionally be absent. The d units provide the first portion of the monomer units that are derivatised with a hydrophobic group, and the b units provide the second portion of the monomer units and are derivatised with a quaternary nitrogen group. When present, the a units provide the third group of monomer units in which the amine groups are derivatised in a different manner to the first or second group.

[0027] When present the c units provide the fourth group of monomer units in which the amine groups are underivatised.

[0028] In the present invention, the hydrophobic group X is preferably selected from a substituted or unsubstituted group which is an alkyl group such as a C4-30 alkyl group, an alkenyl group such as a C4-30 alkenyl group, an alkynyl group such as a C4-30 alkynyl group, an aryl group such as a C5-20 aryl group, a multicyclic hydrophobic group with more than one C4-C8 ring structure such as a sterol (e.g. cholesterol), a multicyclic hydrophobic group with more than one C4-C8 heteroatom ring structure, a polyoxa C1-C4 alkylene group such as polyoxa butylene polymer, or a hydrophobic polymeric substituent such as a poly (lactic acid) group, a poly(lactide-co-glycolide) group or a poly(glycolic acid) group. The X groups may be linear, branched or cyclo groups. Any of the X groups may be directly linked to the d unit (i.e. at the C2 of the monomer unit), or via a functional group such as an amine group, an acyl group, or an amide group, thereby forming linkages that may be represented as X'-ring, X'-NH-, X'-CO-ring, X'CONH-ring, where X' is the hydrophobic group as defined above.

[0029] Preferred examples of X groups include those represented by the formulae CH3(CH2)n-CO-NH- or CH3(CH2)n-NH- or the alkeneoic acid CH3 (CH2)p-CH=CH-(CH2)q-CO-NH-, where n is between 4 and 30, and more preferably between 6 and 20, and p and q may be the same or different and are between 4 and 16, and more preferably 4 and 14. A particularly preferred class of X substituents are linked to the chitosan monomer unit via an amide group, for example as represented by the formula CH3(CH2)nCO-NH-, where n is between 2 and 28. Examples of amide groups are produced by the coupling of carboxylic acids to the amine group of chitosan. Preferred examples are fatty acid derivatives CH3(CH2)nCOOH such as those based on capric acid (n = 8), lauric acid (n = 10), myristic acid (n = 12), palmitic acid (n = 14), stearic acid (n = 16) or arachidic acid (n = 18).

[0030] In the above formula, R1, R2 and R3 are preferably independently selected from a substituted or unsubstituted alkyl group such as a C1-10 alkyl group. R1, R2 and/ or R3 may be linear or branched. Preferably, R1, R2 and R3 are independently selected from methyl, ethyl or propyl groups.

[0031] In the above formula, R8 and R9 are preferably independently selected from hydrogen and a substituted or unsubstituted alkyl group such as a C1-10 alkyl group. R8 and/ or R9 may be linear or branched. Preferably, R8 and R9 are independently selected from methyl, ethyl or propyl groups.

[0032] In the above formula, R4, R5, R6 and R10 present on the C6 or the sugar units are independently selected from hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted ether group, or a substituted or unsubstituted alkene group. Preferred R4, R5, R6 and R10 groups are substituted with one of more hydroxyl groups, or another non-ionic hydrophilic substituent. Examples of R4, R5, R6, and R10 groups are represented by the formulae -(CH2)p-OH, where p is between 1 and 10, and is preferably between 2 and 4, or -(CH2)p-CH(CH2-OH)2 where p is between 1 and 10 or -(CH2)p-C(CH2-OH)r where p is between 1 and 10, and r is 3, or -(CH2CH2OH)p, where p is between 1 and 300.

[0033] The R7 group may be present or absent in the general formula. When absent, it provides a quaternary ammonium functional group that is directly linked to the monomer unit of the chitosan backbone. When the R7 group is present it may be a unsubstituted or substituted alkyl group (e.g. a C1-10 alkyl group) for example as represented by the formula -(CH2)n-, an amine group as represented by the formula -NH-(CH2)n-, or an amide group as represented by the formula -NH-CO-(CH2)n-, where n is 1 to 10 and is preferably 1 to 4. A preferred example of the R7N+R1R2R3 substituent is provided by coupling betaine (-OOC-CH2-N-(CH3)3) to the amine substituent of the b unit providing an amide group such as in: -NH-CO-CH2-N+R1R2R3.

[0034] As indicated, some of the substituents described herein may be either unsubstituted or substituted with one or more additional substituents as is well known to those skilled in the art. Examples of common substituents include halo; hydroxyl; ether (e.g., C1-7 alkoxy); formyl; acyl (e.g. C1-7 alkylacyl, C5-20 arylacyl); acylhalide; carboxy; ester; acyloxy; amido; acylamido; thioamido; tetrazolyl; amino; nitro; nitroso; azido; cyano; isocyano; cyanato; isocyanato; thiocyano; isothiocyano; sulfhydryl; thioether (e.g., C1-7 alkylthio); sulphonic acid; sulfonate; sulphone; sulfonyloxy; sulfinyloxy; sulfamino; sulfonamino; sulfinamino; sulfamyl; sulfonamido; C1-7 alkyl (including, e.g., unsubstituted C1-7 alkyl, C1-7 haloalkyl, C1-7 hydroxyalkyl, C1-7 carboxyalkyl, C1-7 aminoalkyl, C5-20 aryl-C1-7 alkyl); C3-20 heterocyclyl; and C5-20 aryl (including, e.g., C5-20 arboaryl, C5-20 heteroaryl, C1-7 alkyl-C5-20 aryl and C5-20 haloaryl) groups.

[0035] The term "ring structure" as used herein, pertains to a closed ring of from 3 to 10 covalently linked atoms, yet more preferably 3 to 8 covalently linked atoms, yet more preferably 5 to 6 covalently linked atoms. A ring may be an alicyclic ring, or aromatic ring. The term "alicyclic ring," as used herein, pertains to a ring which is not an aromatic ring.

[0036] The term "carbocyclic ring", as used herein, pertains to a ring wherein all of the ring atoms are carbon atoms.

[0037] The term "carboaromatic ring", as used herein, pertains to an aromatic ring wherein all of the ring atoms are carbon atoms.

[0038] The term "heterocyclic ring", as used herein, pertains to a ring wherein at least one of the ring atoms is a multivalent ring heteroatom, for example, nitrogen, phosphorus, silicon, oxygen or sulphur, though more commonly nitrogen, oxygen, or sulphur. Preferably, the heterocyclic ring has from 1 to 4 heteroatoms.

[0039] The above rings may be part of a "multicyclic group".

[0040] Preferably, the amphiphilic carbohydrate compound is quaternary ammonium palmitoyl glycol chitosan (GCPQ).

[0041] The amphiphilic carbohydrate compound is capable of self-assembling into particles in aqueous media without the presence of other agents such as tripolyphosphate.

[0042] The compositions of the present invention may form particulate aggregates. These may be formed by the aggregation of individual amphiphile molecules and the hydrophilic drug and have a mean particle size of between 10 nm and 20 µm.

[0043] Preferably the amphiphilic carbohydrate compound forms nanoparticles which can be loaded with hydrophilic drug. A dispersion of carbohydrate and drug may be formed which is clear or translucent. Generally the amphiphilic compound is mixed with drug and a dispersion is prepared by vortexing and probe sonicating the mixture.

[0044] The mean particle size can readily be determined microscopically or by using photon correlation spectroscopy and is conveniently determined in aqueous dispersions prior to filtration. More preferably, the polymeric micellar aggregates have a minimum mean particle size of at least 10 nm, and more preferably at least 30 nm, and a maximum mean particle size which is preferably 10µm or less.

[0045] Typically, the ratio of amphiphilic carbohydrate compound to drug is within the range of 1:10 - 20:1; a preferred range is 0.5:1 - 10:1 and a more preferred ratio is 1:1 by weight.

[0046] Typically, the ratio of amphiphilic carbohydrate compound to drug to pharmaceutically acceptable carrier may be about 1 - 100 mg: 50 mg : 1g.

[0047] The pharmaceutical composition of this invention may be in a liquid or solid form suitable for intranasal administration.

[0048] A suitable daily dose can be determined based on age, body weight, administration time, etc. While the daily doses may vary depending on the condition and body weight of the patient, and the nature of the drug, a typical intranasal dose is about 0.1 - 120 mg/person/day, preferably 0.5 - 60mg/person/day.

[0049] The invention will now be illustrated by the following Examples, which refer to Figures 1 and 2, wherein:

Figure 1 shows the effect of intranasal LENK in the absence and presence of GCPQ in a Complete Freund's Adjuvant (CFA) rat inflammatory pain model; and

Figure 2 shows assessment of the contribution of central and peripheral mechanisms to the activity of an intranasal LENK-GCPQ formulation in a rat CFA inflammatory pain model.


EXAMPLES


Example 1


Synthesis of Quaternary Ammonium Palmitoyl Glycol Chitosan (GCPQ) Acid Degradation of Glycol Chitosan



[0050] Glycol chitosan (2g) was dissolved in hydrochloric acid (4M, 150 mL) for 20mins a room temperature under constant stirring. The solution was placed in a preheated water bath at 50 °C. At 8 hr the reaction was stopped and the product was removed from the shaking water bath. Molecular weight was controlled by degradation time, i.e. increasing the acid degradation time decreased the molecular weight of the resulting polymer. Previous work has shown that a molecular weight of 13,000 Da was obtained after 8 hr of acid hydrolysis of glycol chitosan with a starting molecular weight of approximately 100,000 Da. The product was purified by exhaustively dialysing (Visking seamless cellulose tubing, molecular weight cut off of 7,000 Da) against deionised water (5 L) with six changes over 24 hr. The dialysate at the end of the dialysis procedure (neutral pH) was subsequently freeze-dried, and the product was recovered as a cream-colored cotton-wool-like material. The degradation yielded 1.06 g (i.e. 53%) of degraded glycol chitosan.

Palmitoylation of Degraded Glycol Chitosan



[0051] Degraded glycol chitosan (500 mg) and sodium bicarbonate (376 mg, - 0.045M) were dissolved in a mixture of absolute ethanol (24 mL) and deionised water (76 mL). To this glycol chitosan solution was added dropwise a solution of palmitic acid N-hydroxysuccinimide (PNS, 792 mg) dissolved in absolute ethanol (150 mL), with continuous stirring over a period of 20 mins. The mixture was then stirred for 72 hr and the product isolated by evaporating off most of the ethanol and extracting 3 times the remaining aqueous phase (100 mL) with diethylether (each time twice the volume of the aqueous phase i.e. 200 mL was used). The aqueous mixture of the polymer was exhaustively dialysed (Visking seamless cellulose tubing, molecular weight cut off = 7,000 Da) against deionised water (5 L) with 6 changes over a 24-hr period and the resultant product freeze-dried to give a white cotton-like solid.

Quaternisation of Palmitoyl Glycol Chitosan



[0052] Palmitoyl glycol chitosan (300 mg) was dispersed in N-methyl-2-pyrrolidone (25 mL) overnight for 12 hr at room temperature. Sodium hydroxide (40 mg, 1 mole as an aqueous solution 0.057M), methyl iodide (1.0 g, 0.44 mL) and sodium iodide (45 mg, as an ethanolic solution, 0.05M) were added and the reaction stirred under a stream of nitrogen at 36 ° C. for 3 hr.

[0053] The quaternary ammonium product was precipitated with diethyl ether (400 mL), filtered and washed twice more with copious amounts of diethyl ether (twice with 300 mL) to give a yellow hygroscopic solid. The quaternised product was dissolved in water (100 mL) to give a yellow solution. The resultant solution was exhaustively dialysed against water (5 L) with six changes over a 24 hr period and the dialysate was passed through a column (1 x 6 cm) packed with Amberlite IRA-96 Cl-. The column was packed with one volume of the resin (30 mL) and subsequently washed with hydrochloric acid solution (90 mL, 1M) followed by deionised water (10 L) to give a neutral pH. The clear eluate from the column was freeze-dried to give quaternary ammonium palmitoyl glycol chitosan (GCPQ) as a transparent fibrous solid. The synthetic yield of GCPQ is between 150-160 mg (i.e. 50-53 %).

Gel permeation Chromatography and Multi-angle Laser Light Scattering (G PC-MALLS)



[0054] The molecular weight of GCPQ was determined by GPC-MALLS equipped with DAWN® EOS™ MALLS (λ= 690 nm), Optilab DSP Interferometric Refractometer (λ= 690 nm) and both quasi-elastic light scattering and light scattering detectors (Wyatt Technology Corporation, USA) using a mobile phase of acetate buffer (0.3 M CH3COONa (anhydrous)/ 0.2 M CH3COOH, pH = 4.5)/ HPLC grade Methanol (35 : 65) at a flow rate 1 ml min-1. Filtered samples (0.2 µm) were injected using a Waters 717 Autosampler into a POLYSEPTM-GFC-P guard column (35 x 7.8 mm, Phenomenx, UK) attached to a POLYSEP TM-GFC-P 4000 column (300 x 7.8 mm, Phenomenx, UK) at a loading concentration of 5 mg mL-1. The data was processed using ASTRA for windows version 4.90.08 software (Wyatt Technology Corporation, USA). The specific refractive index increment (dn/dc) of GCPQ was measured in solvent (as above) at room temperature with an Optilab DSP Interferometric Refractometer (λ= 690 nm). Filtered samples (0.2 µm) ranging from 0.1 - 0.6 mg mL-1 were manually injected using an Injection System (Wyatt Technology Corporation, USA) at a pump flow rate of 0.3 mL min-1. The data was processed using ASTRA for windows version 4.90.08 software (Wyatt Technology Corporation, USA).

1H NMR



[0055] 1H NMR experiments were performed on a Bruker AMX 400 MHz spectrometer (Bruker Instruments, Coventry, U.K.) of acid degraded chitosan in D2O (10 mg mL-1) and GCPQ solutions in CH3OD (10 mg mL-1). Analyses were performed at a temperature of 45 - 50 °C. The level of palmitoylation was calculated by comparing the ratio of palmitoyl methyl protons (δ = 0.89 ppm) to sugar protons (δ = 3.5 - 4.5 ppm) and the level of quaternisation calculated by comparing the ratio of quaternary ammonium (δ = 3.45 ppm) to sugar protons.

Preparation of Self Assembled Polymer Nanoparticles



[0056] Self-assembled polymer amphiphiles were prepared by vortexing (WhirliMixer, Fisherbrand) GCPQ (45 mg) in water for injection BP (B. Braun Melsungen AG, Germany) (1.5 mL) and then by probe sonicating the dispersion (Qsonica) with the instrument set at 30 % of its maximum output for 10 minutes on ice. Particle size was measured by Photon correlation spectroscopy (Malvern Zetasizer 3000HS, Malvern Instruments, UK) at 25 °C. at a wavelength of 633 nm and the data analysed using the Contin method of data analysis. Polymer dispersions were left for 15 mins at room temperature (25 °C.) before particle size was measured. The clear dispersions were then syringe-filtered (0.45 µm, 33 mm Millex GP syringe driven filter unit, PES membrane for sterilisation of aqueous solutions) and the filtered solution was then measured again as above. Measurements were performed in triplicate.

[0057] The morphological examination of the nanoparticles was studied by transmission electron microscopy (TEM). A drop of unfiltered solution was placed on Formvar/Carbon Coated Grid (F1961100 3.05 mm, Mesh 300, Tab Labs Ltd, UK). Excess sample was filtered off with No. 1 Whatman Filter paper and negatively stained with 1% aqueous Uranyl Acetate. Imaging was carried out using an FEI CM120 BioTwin Transmission Electron Microscope (FEI, USA). Digital Images were captured using an AMT digital camera. Polymer nanoparticles (unfiltered) presented a spherical morphology.

Preparation of Self Assembled Polymer NanoParticles (with Drug) for nasal Administration



[0058] GCPQ dispersions (30 mg mL-1) with LENK (30 mg mL-1) were prepared by vortexing (WhirliMixer, Fisher, UK) for 5 minutes in water for injection BP (B. Braun Melsungen AG, Germany) the suspension was then pH adjusted to pH = 5.8 with 1M NaOH prior to probe sonicating (Qsonica) with the instrument set at 30 % of its maximum output for 10 minutes on ice (pH = 5.8). Formulations were filtered (0.8 µm, 13 mm, Acrodisc Syringe Filter, Super Low Protein Binding Non-Pyrogenic Membrane, PALL Life Science). Formulations were left overnight in the fridge. Particle size was measured by Photon correlation spectroscopy (Malvern Zetasizer 3000HS, Malvern Instruments, UK) at 25 °C. at a wavelength of 633 nm and the data analysed using the Contin method of data analysis. Polymer dispersions with LENK were left for 15 mins at room temperature (25° C.) before particle size was measured. The morphological examination of the nanoparticles was studied with TEM. A drop of unfiltered solution was placed on Formvar/Carbon Coated Grid (F1961100 3.05 mm, Mesh 300, Tab Labs Ltd, UK). Excess sample was filtered off with No. 1 Whatman Filter paper and negatively stained with 1% aqueous Uranyl Acetate. Imaging was carried out under a FEI CM120 BioTwin Transmission Electron Microscope (FEI, USA). Digital Images were captured using an AMT digital camera. Polymer nanoparticles (unfiltered) presented a spherical morphology.

Analysis of Peptide Drug Loaded Polymers



[0059] The quantitative determination of LENK was performed on an Agilent high performance liquid chromatography (HPLC) system consisting of a binary pump (1220 Infinity LC Gradient System VL) equipped with a variable wavelength UV detector and with an Onyx monolithic C18 column (5 µm, 4.6 mm x 10 mm) with a C18 guard column (Phenomenex, UK). The mobile phase consisted of 82% water: 18% acetonitrile: 0.02% trifluoroacetic acid. Sample elution was monitored at a UV absorption wavelength of 214 nm, at a flow rate of 1.0 mL min-1 at 30° C. with an injection volume of 10 µL. The retention time was 6.6 minutes for LENK and the lowest detection limits were 1 µg mL-1.

Results for Peptide Drug Loaded Polymer Dispersions for Intranasal Administration



[0060] Drug - Polymer dispersions presented as clear or translucent formulations and consisted of two populations of particles which had sizes of 20nm and 500nm. The drug content was analysed at 80% of the initial amount.

In Vivo Studies Intranasal Administration Pharmacodynamics-Animals



[0061] Sprague Dawley rats (200 - 250 g) were housed four per cage in an air conditioned unit maintained at 20 - 22°C and 50 - 60% humidity and were allowed free access to standard rodent chow and water. Lighting was controlled on a twelve-hour cycle, lights on at 07.00 h. Animals were habituated for 7 days prior to experimentation and acclimatised to the procedure room for 1 hr prior to testing. All protocols were conducted under a UK Home office licence and approved by a local ethics committee.

Formulations



[0062] Rats were intranasally administered water for injection (0.05 ml), intranasal LENK hydrochloride salt in water 30mg mL-1, (7.5 mg kg-1, pH = 5.8, 50µL), GCPQ-LENK in water composed of LENK hydrochloride salt 30mg mL-1, (7.5 mg kg-1, pH = 5.8, 50µL) and GCPQ (30 mg mL-1). The administered intranasal volume of the formulations was set to a maximum of 60µL per rat. The administered volume was adjusted based on the high performance liquid chromatography (HPLC) quantification of LENK and the body weight of each animal. The maximum volume was dosed for placebo (water pH = 5.8) receiving rats. Animals were briefly anesthetised with isoflurane and intranasally administered formulations using an insulin syringe attached to PE10 tubing (15 mm), the tubing was inserted into one of nares.

Complete Freund's Adjuvant (CFA) induced Chronic Inflammatory Pain



[0063] Rats received an intraplantar injection of 100 µL of CFA (Mycobacterium tuberculosis heat killed suspended in 85% paraffin oil and 15% mannide monooleate 1mg/ml, Sigma) using a glass Hamilton syringe with a 25G needle. CFA caused hind paw oedema and mechanical hypersensitivity was evaluated 24 hr after CFA injection.

Measurement of Mechanical Hypersensitivity



[0064] Mechanical hypersensitivity was evaluated. Rats were individually placed on an elevated plastic mesh (0.5 cm2 perforations) in a clear plastic cage. Two habituations to the evaluation chambers for at least 5min duration each were performed on two different days. A baseline measurement was taken on test day pre-CFA. Mechanical hypersensitivity was assessed by the sensitivity to the application of von Frey hairs (Ugo Basile, Switzerland). The von Frey filaments (1.4, 2, 4, 6, 8, 10, 15, 26g) were presented perpendicularly to the plantar surface of the injected paw in ascending order, and held in this position for 5 s with enough force to cause a slight bend in the filament. Positive responses included an abrupt withdrawal of the hind paw or a response was noted if the paw was sharply withdrawn or there was flinching upon application of the hair. Once a positive withdrawal response was established, the paw was retested, starting with the next descending von Frey hair until no response occurred. The lowest amount of force required to elicit a response was recorded as the paw withdrawal (g). Mechanical allodynia was defined as a significant decrease in withdrawal thresholds to von Frey hairs application. The 26 g hair was selected as the upper limit cut-off for testing.

[0065] To test formulation effects on mechanical allodynia, rats were evaluated for thresholds 24 hr after CFA injection; they were then randomised according to their threshold values and dosed with formulations. Rats were evaluated by an observer blinded to the treatments.

Central and Peripheral Contributions to Analgesia



[0066] To assess the contribution of central and peripheral mechanisms of formulation analgesia, non-selective opioid antagonists were administered subcutaneously. naloxone hydrochloride (15 mg mL-1, 7.3 mg kg-1 90µL, MP Biomedicals, UK) and naloxone methiodide quaternary ammonium salt of naloxone which is peripherally restricted (20mg mL-1, 10mg kg-1, 90µL, Sigma). These antagonists were concomitantly administered with nasal formulations.

Statistical Analysis



[0067] Results are presented as mean ± S.E.M. and the data were analyzed by two-way analysis of variance (ANOVA) followed by Bonferroni post hoc test. All statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA). P values of less than 0.05 were considered significant.

Pharmacodynamics Results



[0068] Figure 1 shows the effect of intranasal LENK in the absence and presence of GCPQ in a rat CFA inflammatory pain model (mean ± SEM n = 6; two way ANOVA with repeated measure followed by Bonfferoni post hoc test). In Figure 1, * represents a statistically significant difference between the vehicle and treatment groups, and # represents a statistically significant difference between LENK alone and LENK-GCPQ.

[0069] 100µL CFA was injected into the plantar surface of the left back paw. Inflammation was allowed to develop for 24 hr. Animals were randomised on the post-CFA baseline prior to receiving an intranasal administration of vehicle (water, 50 µL/rat), LENK 7.5 mg kg-1 (pH = 5.8, 50 µL), LENK-GCPQ (7.5 mg kg-1 LENK and 7.5 mg kg-1 GCPQ, pH = 5.8, 50 µL). GCPQ19082013LG (mole% palmitoylation = 13 %, mole % quaternary ammonium groups = 9.1 %, molecular weight = 22 KDa, Mw/ Mn = 1.031). Paw withdrawal to von Frey hairs (1.4, 2, 4, 6,8,10,15,26 g) was assessed 20 min, 40 min, 1, 2, 3 and 4 hr using the up-down method of assessment.

[0070] Pre-CFA baseline paw withdrawal force was 24.4 ± 4 g. Post- CFA (24 hr) baseline was 3.3 ± 1.3 g. No statistical difference was observed between LENK solution (30 mg mL-1) and the vehicle control at any of the time points measured (20, 40 min, 1, 1.5, 2, 3 and 4 hr). The LENK-GCPQ (30 mg mL-1 LENK) formulation significantly reversed the nociception for up to 4 hr, in comparison to the vehicle control and the LENK solution.

[0071] To assess the contribution of central and peripheral mechanisms of action, the non-specific opioid antagonists naloxone and its peripherally restricted quaternary ammonium salt, naloxone methioide, were used.

[0072] Figure 2 illustrates the assessment of the contribution of central and peripheral mechanisms of action of intranasal LENK-GCPQ formulations in CFA inflammatory pain rats (mean ± SEM n = 6, two way ANOVA with repeated measure followed by Bonfferoni post hoc test). In this figure * represents a statistically significant difference between the vehicle and treatment groups.

[0073] 100 µL CFA was injected into the plantar surface of the left back paw. Inflammation was allowed to develop for 24 hr. Animals were randomised on the post-CFA baseline prior to receiving an intranasal administration of vehicle (water, 50 µL/rat) or LENK-GCPQ (7.5 mg kg-1 LENK and 7.5 mg kg-1 GCPQ, pH = 5.8, 50 µL). GCPQ25092013LG (mole% palmitoylation = 15.5 %, mole% quaternary ammonium groups = 8.7 %, molecular weight = 20 KDa, Mw/ Mn = 1.061). Concomitantly subcutaneous injections were also administered; vehicle (water for injection, 90 µL), opioid antagonist Naloxone (Nal 7.3 mg kg-1 subcutaneously, 90 µL) or the peripherally restricted opioid antagonist Naloxone Methiodide (NM, 10 mg kg-1, subcutaneously 90 µL). Paw withdrawal to von Frey hairs (1.4, 2, 4, 6, 8, 10, 15, 26 g) was assessed 20 min, 40 min, 1, 2, and 3 hr using the up-down method of assessment.

[0074] As previously shown LENK-GCPQ formulation was antinociceptive at all time points measured (20, 40 min, 1, 2 and 3 hr) in the absence of antagonist. In the presence of Naloxone LENK-GCPQ antinociception was completely abolished up to 2 hr. At the 3 hr time point antinociception returned presumably due to the short half-life of Naloxone. In contrast, in the presence of the peripherally restricted antagonist, Naloxone methiodide, LENK-GCPQ antinociception was completely unaffected therefore indicating that there is no peripheral mechanism involved in the antinociception of LENK GCPQ.

Example 2 - Comparison of Invention with Prior Art


Methods


Trimethylchitosan synthesis 2-step reaction (Prior art)



[0075] Two step synthesis was carried out using essentially the same method as reported by Sieval, A.B., et al., Preparation and NMR characterization of highly substituted N-trimethyl chitosan chloride. Carbohydrate polymers, 1998. 36(2-3): p. 157-165. Briefly 2g chitosan (Sigma, UK) was suspended in 80ml of 1-methyl-2-pyrrolidinone in 3 neck flask, in a stabilised oil bath at 60°C under reflux. Sodium iodide (4.8g) was dissolved in 11ml of NaOH (15%, 3.84M) and added to the chitosan. The system was purged of air with nitrogen prior to the addition of methyl iodide (11.5ml) and reacted for 1hr. The product was precipitated with ethanol and thereafter isolated by centrifugation (2000rpm at 6°C for 3min). The product was placed in a vacuum filter and washed twice with ether (300ml total) to remove all the ethanol until it was quite dry. The product was then resuspended in NMP (80ml) stirring for 30mins at 60°C uncapped to remove the majority of the ether. Subsequently, 4.8g sodium iodide and 11ml of 15% NaOH solution, and 7ml of methyl iodide was added and the reaction and stirred under reflux for 30mins. A further addition of methyl iodide (5ml) and 0.6 g NaOH pellets were added to the reaction which continued for a further 90mins. The reaction mixture was precipitated with ethanol as before and centrifuged to isolate, the ethanol was removed and the product was washed with ether (100ml). The product was left overnight to dry and resuspended in NaCl (40ml, 10%). This was then dialysed and freeze dried. 1H NMR spectra were measured in D2O at 80 °C using AV400 MHz spectrometer.

TMC synthesis 1 -step reaction



[0076] One step synthesis was carried out using essentially the same method as reported by Sieval et al mentioned above. Briefly 2g chitosan, 4.8g sodium iodide were suspended in 80ml of NMP in 3 neck flask, in a stabilised oil bath at 60°C under reflux (3hrs). Once dissolved 11ml of NaOH (15%, 3.84M, 2.8g/ 18.6ml) followed by 11.5ml methyl iodide were added. The reaction was stirred for 1hr. The product was precipitated with ethanol and thereafter isolated by centrifugation (2000rpm at 6°C for 3min). The material was dissolved in 40ml water to which 250ml 1M HCL in ethanol was added and stirred overnight. The product was isolated by centrifugation (2000rpm at 6°C for 3min) and the pellet washed twice with ethanol and isolated by centrifugation. The product was placed in a vacuum filter and washed twice with ether (300ml total). The semi-dry product was resuspended in water and dialysed for 24 hrs with 6 changes. Product was freeze dried.

1H NMR



[0077] 1H NMR experiments were performed on a Bruker AV 400 MHz spectrometer (Bruker Instruments, Coventry, U.K.) of TMC in D2O (10 mg/ml). Analyses were performed at a temperature of 80°C with suppression of the water peak. The degree of methylation was calculated as a percentage,

[(CH3)3] is the integral of the chemical shift of the trimethyl amino group at 3.3 ppm, and [H] is the integral of the 1H peaks between 4.7 and 5.7 ppm (Polnok, A., et al., Influence of methylation process on the degree of quaternization of N-trimethyl chitosan chloride. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2004. 57(1): p. 77-83.)

TMC particles (40% methylation)



[0078] TMC laded particles were prepared as Kumar, M., et al., Evaluation of neuropeptide loaded trimethyl chitosan nanoparticles for nose to brain delivery. International journal of biological macromolecules, 2013. 61C: p. 189-195. 24mg TMC (40%) in 12ml water with 138mg LENK base. 7.3ml TPP (0.6mg/ml) dropped into the stirred TMC through 16G needle. The formulation was stirred overnight. Nanoparticles were pelleted by centrifugation (12000 xg 30mins at 8°C). The supernatant was analysed for LENK content and the pellet resuspended in 0.3ml injection water 9.6mg/ 0.3ml = 32mg/ml, pH6. Particle size was measured by Photon Correlation Spectroscopy (Malvern Zetasizer 3000HS, Malvern Instruments, UK) at 25 °C at a wavelength of 633 nm and the data analysed using the Contin method of data analysis. The morphological examination of the nanoparticles was studied with TEM. A drop of unfiltered solution was placed on Formvar/Carbon Coated Grid (F1961100 3.05 mm, Mesh 300, Tab Labs Ltd, UK). Excess sample was filtered off with No. 1 Whatman Filter paper and negatively stained with 1% aqueous Uranyl Acetate. Imaging was carried out under a FE1 (Ex. Philips) CM120 BioTwin Transmission Electron Microscope (TEM). Digital Images were captured using an AMT (digital) camera. Polymer nanoparticles (unfiltered) presented a spherical morphology.

TMC particles (15% methylation)



[0079] TMC laded particles were prepared as Kumar et al Evaluation of neuropeptide loaded trimethyl chitosan nanoparticles for nose to brain delivery. International journal of biological macromolecules, 2013. 61C: p. 189-195. 29mg TMC (15%) in 14.5ml water with 125mg LENK base. 8.78ml TPP (0.6mg/ml) was dropped into the stirring TMC through 16G needle. Nanoparticles were pelleted by centrifugation (12000 xg 30mins 8°C). The formulation was stirred overnight. The supernatant was analysed for LENK content (HPLC) and the pellet resuspended in 0.3ml injection water 6.1mg/0.3ml =20mg/ml, adjusted from pH 4 to pH 5 with NaOH. Nanoparticles size and morphology were analysed as above.

Preparation of Self Assembled Polymer NanoParticles



[0080] Polymer dispersions (30 mg/mL) with LENK (30 mg/mL) were prepared according to Example 1.

Pharmacodynamics



[0081] Nasal dosing and mechanical hypersensitivity was assessed as before.

Results for Peptide Drug Loaded Polymer Dispersions for Intranasal Administration



[0082] Drug-Polymer dispersions presented as a slight opalescent suspension with a 24-40% loading efficiency, z-average mean of 855.2 ± 19.85 nm and 601.6 ± 89.2 nm for 40% and 15% methylated chitosan respectively with a polydispersity index = 0.292 and 0.659 respectively.

Measurement of Paw Withdrawal Force



[0083] 100µl CFA was injected into the plantar surface of the left back paw. Inflammation was allowed to develop for 24hr. Animals were randomised on the post-CFA baseline prior to receiving intranasal administration of vehicle (water pH 50 µl/rat), LENK:GCPQ 7.5 mg/kg LENK: 7.5 mg/kg GCPQ (pH 5.8, 50 µl), trimethylchitosan (TMC, 15% methylation) equivalent dose 5mg/kg, TMC (40% methylation, equivalent LENK dose of 7.5mg/kg. GCPQ (Batch # 09062014AI, degree of palmitoylation = 21.54mole%, degree of quaternisation = 12.08mole%, Mw 16.2 KDa, Mn 15.9 KDa, Mw/Mn 1.018). The paw withdrawal to Von Frey hairs fibres (1.4, 2, 4, 6,8,10,15,26 g) was assessed at 30 min, 1, 1.5, 2, 3 and 4hr using the up down method of assessment.

Pharmacodynamics Results



[0084] Pre-CFA baseline paw withdrawal force was 24.6 ± 3.7 g. Post- CFA (24hr) baseline was 4.8 ± 1.3 g. No statistical difference was observed between TMC 15% and the vehicle control at any of the time points measured (30 min, 1, 1.5, 2, 3 and 4 hr). TMC 40% was significantly different at the 30min time point only. The LENK-GCPQ (30 mg/ml LENK) formulation significantly reversed the nociception for up to 3hr, in comparison to the vehicle control.
Intranasal LENK GCPQ was a superior anti-nociceptive agent when compared to intranasal TMC LENK.

[0085] The following table shows the effect of intranasal LENK GCPQ vs TMC LENK in CFA inflammatory pain in rats. The values are paw withdrawal force, given in g.
 VEHICLELENK GCPQ TMC 15% TMC 40% 
-24h 24.2±1.8 24.2±1.8   24.2±1.8   26.0±0.0  
0 4.7±0.8 5.0±0.4   5.0±0.5   4.8±0.4  
0.5 5.0±0.4 18.7±2.3 ** 7.3±0.8   10.8±1.6 *
1 4.3±0.3 14.3±2.5 * 5.3±0.4 # 7.8±1.7  
1.5 4.7±0.4 14.0±2.7   5.3±0.4   4.4±0.4  
2 4.7±0.4 9.7±0.3 *** 5.0±0.7 ## 4.0±0.0 ##
3 4.0±0.0 8.0±0.9 * 4.7±0.4   4.0±0.0 #
4 4.7±0.4 7.0±0.7   5.3±0.4   4.8±0.4  

Key



[0086] Mean ± SEM n=6. Two way ANOVA with repeated measure followed by Games Howell post hoc test
* = statistically significant difference between the vehicle vs treatment, # = statistically significant difference between the treatment vs LENK GCPQ


Claims

1. A composition comprising a hydrophilic neuroactive peptide drug and an amphiphilic carbohydrate compound for use in the treatment of pain wherein the composition is intranasally administered to the human or animal body, wherein the amphiphilic carbohydrate compound is represented by the general formula:

wherein a + b + c + d = 1.000 and

a is between 0.00 and 0.970

b is between 0.01 and 0.990,

c is between 0.000 and 0.970, and

d is between 0.01 and 0.990;

and wherein:

X is a hydrophobic group;

R1, R2 and R3 are independently selected from a substituted or unsubstituted alkyl group;

R4, R5, R6 and R10 are independently selected from hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted ether group, or a substituted or unsubstituted alkene group;

R7 may be present or absent and, when present, is an unsubstituted or substituted alkyl group, an unsubstituted or substituted amine group or a substituted or unsubstituted amide group;

R8 and R9 are independently selected from hydrogen and either a substituted or unsubstituted alkyl group, a substituted or unsubstituted ether group, or a substituted or unsubstituted alkene group;
or a salt thereof.


 
2. A composition for use according to claim 1 wherein the amphiphilic carbohydrate compound is in the form of nanoparticles which are capable of self-assembly in aqueous media.
 
3. A composition for use according to claim 1 or 2 for use in the delivery of the drug to the brain of the human or animal body.
 
4. A composition for use according to any preceding claim wherein the hydrophilic drug is a neuropeptide selected from enkephalin, neuropeptide S, dalargin, orexin, vasopressin, leptin, cholecystokinin, dynorphin, detorphin I, neurotensin and oxytocin.
 
5. A composition for use according to any preceding claim wherein the drug is Leucine[5]-Enkephalin (LENK) or Methionine[5]-Enkephalin (MENK).
 
6. A composition for use according to any preceding claim which is in the form of a polymeric aggregate having a mean particle size between 10nm and 20µm.
 
7. A composition for use according to any preceding claim wherein the amphiphilic carbohydrate compound is quaternary ammonium palmitoyl glycol chitosan (GCPQ).
 
8. A composition for use according to any preceding claim wherein the ratio of amphiphilic compound to drug in the composition is in the range 0.5:1 - 10:1 by weight.
 
9. A composition for use according to any preceding claim which is formulated as a pharmaceutical composition together with one or more pharmaceutically acceptable excipients.
 


Ansprüche

1. Zusammensetzung, umfassend ein hydrophiles, neuroaktives Peptid-Medikament und eine amphiphile Kohlenhydratverbindung zur Verwendung bei der Behandlung von Schmerzen, wobei die Zusammensetzung dem humanen oder tierischen Körper intranasal verabreicht wird, wobei die amphiphile Kohlenhydratverbindung durch die folgende allgemeine Formel dargestellt wird:

wobei a + b + c + d = 1,000 und

a von 0,00 bis 0,970 beträgt,

b von 0,01 bis 0,990 beträgt,

c von 0,000 bis 0,970 beträgt, und

d von 0,01 bis 0,990 beträgt;

und wobei:

X eine hydrophobe Gruppe ist;

R1, R2 und R3 unabhängig aus einer substituierten oder unsubstituierten Alkylgruppe ausgewählt sind;

R4, R5, R6 und R10 unabhängig aus Wasserstoff, einer substituierten oder unsubstituierten Alkylgruppe, einer substituierten oder unsubstituierten Ethergruppe oder einer substituierten oder unsubstituierten Alkengruppe ausgewählt sind;

R7 vorhanden oder nicht vorhanden sein kann, und wenn er vorhanden ist, eine unsubstituierte oder substituierte Alkylgruppe, eine unsubstituierte oder substituierte Aminogruppe oder eine substituierte oder unsubstituierte Amidgruppe ist;

R8 und R9 unabhängig aus Wasserstoff und entweder einer substituierten oder unsubstituierten Alkylgruppe, einer substituierten oder unsubstituierten Ethergruppe oder einer substituierten oder unsubstituierten Alkengruppe ausgewählt sind; oder ein Salz davon.


 
2. Zusammensetzung zur Verwendung nach Anspruch 1, wobei die amphiphile Kohlenhydratverbindung in der Form von Nanopartikeln vorliegt, die sich in wässrigen Medien selbst anordnen können.
 
3. Zusammensetzung zur Verwendung nach Anspruch 1 oder 2 zur Verwendung bei der Abgabe des Medikaments an das Gehirn des humanen oder tierischen Körpers.
 
4. Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, wobei das hydrophile Medikament ein Neuropeptid ist, ausgewählt aus Enkephalin, Neuropeptid S, Dalargin, Orexin, Vasopressin, Leptin, Cholecystokinin, Dynorphin, Detorphin I, Neurotensin und Oxytocin.
 
5. Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, wobei das Medikament Leucin[5]-Enkephalin (LENK) oder Methionin[5]-Enkephalin (MENK) ist.
 
6. Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, die in der Form eines polymeren Aggregats vorliegt, das eine durchschnittliche Partikelgröße von 10 nm bis 20 µm aufweist.
 
7. Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, wobei die amphiphile Kohlenhydratverbindung ein quaternäres Ammoniakpalmitoylglykolchitosan (GCPQ) ist.
 
8. Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, wobei das Verhältnis der amphiphilen Verbindung zu dem Arzneimittel in der Zusammensetzung im Bereich von 0,5:1 bis 10:1 nach Gewicht beträgt.
 
9. Zusammensetzung zur Verwendung nach einem der vorhergehenden Ansprüche, die zusammen mit einem oder mehreren pharmazeutisch verträglichen Hilfsstoffen als eine pharmazeutische Zusammensetzung formuliert ist.
 


Revendications

1. Composition comprenant un médicament peptidique neuroactif hydrophile et un composé d'hydrate de carbone amphiphile pour une utilisation dans le traitement de la douleur, dans laquelle la composition est administrée par voie intranasale au corps humain ou animal, dans laquelle le composé d'hydrate de carbone amphiphile est représenté par la formule générale :

dans laquelle a + b + c + d = 1,000 et

a est compris entre 0,00 et 0,970

b est compris entre 0,01 et 0,990,

c est compris entre 0,000 et 0,970, et

d est compris entre 0,01 et 0,990 ;

et dans laquelle :

X est un groupe hydrophobe ;

R1, R2 et R3 sont indépendamment choisis dans un groupe alkyle substitué ou non substitué ;

R4, R5, R6 et R10 sont indépendamment choisis parmi un atome d'hydrogène, un groupe alkyle substitué ou non substitué, un groupe éther substitué ou non substitué, ou un groupe alcène substitué ou non substitué ;

R7 peut être présent ou absent et, lorsqu'il est présent, est un groupe alkyle non substitué ou substitué, un groupe amine non substitué ou substitué ou un groupe amide substitué ou non substitué ;

R8 et R9 sont indépendamment choisis parmi un atome d'hydrogène et l'un ou l'autre d'un groupe alkyle substitué ou non substitué, d'un groupe éther substitué ou non substitué ou d'un groupe alcène substitué ou non substitué ; ou un sel de celle-ci.


 
2. Composition pour une utilisation selon la revendication 1, dans laquelle le composé d'hydrate de carbone amphiphile se présente sous la forme de nanoparticules qui sont aptes à s'auto-assembler dans un milieu aqueux.
 
3. Composition pour une utilisation selon la revendication 1 ou 2, pour une utilisation dans l'administration du médicament au cerveau du corps humain ou animal.
 
4. Composition pour une utilisation selon une quelconque revendication précédente, dans laquelle le médicament hydrophile est un neuropeptide choisi parmi l'encéphaline, le neuropeptide S, la dalargine, l'orexine, la vasopressine, la leptine, la cholécystokinine, la dynorphine, la détorphine I, la neurotensine et l'oxytocine.
 
5. Composition pour une utilisation selon une quelconque revendication précédente, dans laquelle le médicament est de la Leucine[5]-Encéphaline (LENK) ou de la Méthionine[5]-Encéphaline (MENK)
 
6. Composition pour une utilisation selon une quelconque revendication précédente qui se présente sous la forme d'un agrégat polymère ayant une taille de particule moyenne entre 10 nm et 20 µm.
 
7. Composition pour une utilisation selon une quelconque revendication précédente, dans laquelle le composé d'hydrate de carbone amphiphile est du palmitoyl glycol chitosane d'ammonium quaternaire (GCPQ).
 
8. Composition pour une utilisation selon une quelconque revendication précédente, dans laquelle le rapport entre le composé amphiphile et le médicament dans la composition est dans la plage de 0,5:1 à 10:1 en poids.
 
9. Composition pour une utilisation selon une quelconque revendication précédente qui est formulée en tant que composition pharmaceutique conjointement avec un ou plusieurs excipients pharmaceutiquement acceptables.
 




Drawing











Cited references

REFERENCES CITED IN THE DESCRIPTION



This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description




Non-patent literature cited in the description